Introduction
The incidence of esophageal adenocarcinoma is increasing steadily in North America and Europe (Bytzer et al., 1999) . Gastroesophageal reflux disease, which facilitates the reflux of acidic and alkaline secretions into the esophagus, is a primary risk factor for Barrett's esophagus (BE), a precancerous condition in which the squamous epithelium of the esophagus is replaced by a metaplastic, columnar-lined epithelium. This metaplastic epithelium is susceptible to malignant transformation resulting in Barrett's associated adenocarcinoma (BAA), which has a poor 5-year survival rate. The cost effectiveness of endoscopic surveillance of the BE population is controversial, as only a small number will develop BAA, leading to the proposal of limiting surveillance to those at highest risk, particularly in those in which BE is accompanied by high-grade dysplasia (Ellis Jr and Loda, 1997) .
The uncertainty surrounding the grading of dysplasia has generated intense interest in defining the genetic and epigenetic events that accompany the progression of BE to BAA in order to better predict who is at risk for malignancy. Some of the principal molecular changes include those related to cell cycle control. For example, increased cyclin D1 expression has been reported in nearly half of cases of BE (Jenkins et al., 2002) , in both nondysplastic and dysplastic lesions. In addition, in a case-control analysis of BE biopsy specimens, there was a significantly increased risk of progression to BAA among those whose biopsies were cyclin D1 positive (Bani-Hani et al., 2000) . Hypermethylation of the promoter of p16, the cyclin-dependent kinase inhibitor of the cyclin D1-cdk4/6 complex, is also an early event, and has been reported in nearly one-third of BE lesions (Jenkins et al., 2002) .
Expression of p27 has also been studied in the progression from BE to BAA (Singh et al., 1998) . p27 levels are low in the majority of cases of BAA, in which it is targeted for degradation. We showed that cytoplasmic localization of p27, resulting in its functional inactivation, occurs in a subset of BAA (Singh et al., 1998) . Low p27 expression or its nuclear exclusion in BAA correlates with higher histologic grade, depth of invasion, presence of lymph node metastases and decreased survival, and therefore defines a subset of tumors with aggressive biologic behavior (Singh et al., 1998) . Our group has recently developed a mouse model in which esophagojejunostomy-induced reflux combined with carcinogen exposure results in a high prevalence of both BE and BAA (Xu et al., 2000) . In this model, the rate of premalignant metaplasia and malignant transformation of the esophageal mucosa is significantly enhanced in a p27 null background (Ellis et al., 2001) . Taken together, these data suggest a role for p27 in epithelial protection as well as in the prevention of malignant progression.
The overexpression of cyclin D1 as well as the loss of expression of endogenous cyclin-dependent kinase (cdk) inhibitors during the development of BE and BAA suggests that pharmacologic inhibition of cdk activity may represent a rational, targeted chemoprevention strategy. Flavopiridol, an analogue of a naturally occurring flavonoid isolated from the stem bark of Dysoxylum binectariferum, is a pan-inhibitor of cdk's currently in clinical development. Flavopiridol directly competes with the ATP substrate and inhibits cdk's governing cell cycle progression with IC 50 's of 100-400 nM (Sedlacek, 2001 ). In addition, flavopiridol inhibits cdk9, part of the pTEFb-cdk9 complex, and globally affects cellular transcription, with the most profound effects on the synthesis of mRNAs with short half-lives, including those encoding growth and apoptosis regulators (Chao and Price, 2001; Lam et al., 2001) . Effects on cdk9 may underlie the transcriptional repression of cyclin D1 by flavopiridol (Carlson et al., 1999) .
In a wide variety of solid tumor cell lines, including those established from carcinomas arising in Barrett's mucosa, flavopiridol causes arrest at both the G1 and G2 phases of the cell cycle, consistent with its inhibition of cdk2, 4, 6 and 1 (Schrump et al., 1998; Sedlacek, 2001 ). In addition, flavopiridol also induces apoptosis in esophageal carcinoma cell lines, such that the combined effects of cell cycle arrest and apoptosis result in profound inhibition of tumor cell proliferation (Schrump et al., 1998) . Decreased cyclin D1 has also been documented following flavopiridol exposure in esophageal carcinoma cell lines (Schrump et al., 1998) .
The current study was designed to determine whether flavopiridol could reduce the prevalence of BE and BAA in p27 knockout mice and to concomitantly demonstrate molecular targeting in metaplastic and neoplastic lesions.
Results
Flavopiridol protects the esophageal mucosa from developing BE and BAA To determine whether the cyclin-dependent kinase inhibitor flavopiridol could protect the esophageal mucosa from malignant transformation in a mouse model of BE and BAA, 121 8-week-old p27 knockout mice underwent esophagojejunostomy, followed 1 week later by weekly exposure for 20 weeks to N-methyl-N-benzylnitrosamine (MBN), a carcinogen with a predilection for inducing esophageal cancer. The experimental group (n ¼ 71) also received 5 mg/kg/day of flavopiridol, 5 days a week, administered by intraperitoneal injection. The control group (n ¼ 50) received carcinogen and diluent.
Despite the more prolonged exposure to flavopiridol than previously reported in xenograft experiments in nude mice (Arguello et al., 1998; Patel et al., 1998) , animals in the experimental group maintained their weight to the same extent as those in the control group. For animals that received carcinogen and diluent, the average weight prior to surgery was 27.572.4 and 23.571.7 g prior to killing. Mice treated with carcinogen and flavopiridol weighed on average 27.471.1 g prior to surgery and 23.971.4 g after the 20 weeks of drug exposure prior to killing. BE ( Figure 1a and inset), confirmed by the expression of cdx2 (Figure 1b) , a marker of intestinal metaplasia (Guo et al., 2004; Phillips et al., 2003) , was observed in only 5/71 (7%) animals treated with flavopiridol, while 13/50 (26%) animals in the control group developed BE (P ¼ 0.0079) (Figure 2 ). Concurrent BE and BAA was present in four mice in the diluent group and in none in the flavopiridol-treated arm.
Administration of flavopiridol also resulted in a highly significant (P ¼ 0.0098), threefold reduction in Flavopiridol protects the esophageal mucosa from developing squamous cell carcinoma
The carcinogen exposure in this model also predisposes mice to develop squamous cell esophageal carcinoma. Whereas 14/50 (28%) of p27 knockout mice in the control group developed squamous cell carcinoma (SCC), this was the case in only 3/71 (4%) of flavopiridol-treated mice (P ¼ 0.0003) (Figure 2 ). In the combined analysis of adeno-and squamous carcinomas, the overall cancer rate was significantly decreased in flavopiridol-treated animals (11/71, 15%) in comparison to untreated animals (30/50, 60%) (Po0.0001) (Figure 2 ).
Flavopiridol affects the size of esophageal tumors
Cancers that developed in mice treated with flavopiridol were significantly smaller than the cancers identified in diluent-treated animals. The average size (7s.d.) of BAA lesions in diluent-treated mice was 389271485 mM, compared with 11047653 mM in flavopiridol-treated mice (P ¼ 0.0061).
Molecular targeting of flavopiridol in tumors
In order to investigate whether known cdk target genes were downregulated following flavopiridol treatment, we first analysed levels of cyclin D1 in control and drugtreated animals by immunohistochemistry (IHC). Among tumors in control-treated animals, the mean number of nuclei positive for cyclin D1 expression was 45% (76.8), in contrast to 11% (73.4) in tumors from flavopiridol-treated animals (Po0.016) (representative tumor shown in Figure 3a and b) .
We also sought to assess the level of phosphorylation of the retinoblastoma (Rb) protein. However, because so few tumors developed in flavopiridol-treated animals, all of which were small in size, we were unable to generate an adequate number of sections to fully analyse Rb phosphorylation. Nonetheless, in each of eight adenocarcinomas in diluent-treated mice, approximately 80% of nuclei stained either moderately or strongly with an antibody recognizing Rb phosphorylated at the S249/ 252 site (Figure 3c ). In contrast, in one of two tumors analysed in flavopiridol-treated mice, weak to absent staining with this antibody was observed (Figure 3d ), while levels of total Rb were preserved (not shown).
As the S249/252 site is phosphorylated by cyclin D1-cdk4, reduced phosphorylation at this site in the tumors of flavopiridol-treated mice could be related to direct cdk inhibition or to depletion of cyclin D1. To determine whether there was any evidence for direct cdk inhibition, we analysed the T821 phospho-Rb site. This site has been reported to be targeted by cdk2 and its phosphorylation should not be affected if the primary molecular consequence in response to flavopiridol is cyclin D1 depletion alone (Zarkowska and Mittnacht, 1997) . Figure 4 demonstrates that T821 staining is reduced in this tumor compared to a similar tumor in a mouse that received diluent alone, suggesting that direct cdk2 inhibition occurred in vivo during the course of exposure to flavopiridol. Consistent with reduced levels of phosphorylated Rb, PCNA staining was also decreased in this tumor compared to tumors that developed in diluent-treated animals (not shown). The other tumor analysed from the flavopiridol-treated population did not demonstrate evidence of flavopiridol-mediated cdk inhibition, as it maintained robust expression of cyclin D1, phosphorylated Rb as well as PCNA.
Discussion
We have previously demonstrated that the cyclindependent kinase inhibitor p27 is inactivated in the majority of BAA as a result of either ubiquitin-mediated Flavopiridol reduces prevalence of BE and BAA in p27 KO mice M Lechpammer et al degradation or altered subcellular localization. This prompted us to generate a mouse model in which surgically induced gastroduodenal-esophageal reflux coupled with carcinogen results in both BE and BAA (Xu et al., 2000) . Subsequently, we demonstrated that the rates of premalignant and malignant events are enhanced in a p27-null background (Ellis et al., 2001) . Here, we show that flavopiridol significantly reduces the prevalence of BE in p27 knockout mice. Our data suggest that flavopiridol may be an effective pharmacologic p27 replacement, affording significant epithelial protection despite concomitant experimentally induced reflux and carcinogen exposure.
Administration of flavopiridol also resulted in a significant reduction in the prevalence of adenocarcinoma. As adenocarcinomas of the esophagus in humans with gastroesophageal reflux most likely result from a progression of BE, through Barrett's associated dysplasia to BAA, the decrease in adenocarcinoma prevalence we have seen in flavopiridol-treated mice is consistent with the reduced rate of BE in these animals. Therefore, flavopiridol is effective chemoprevention in a cdk inhibitor-deficient model that mimics the human disease.
As in our previous experiments (Ellis et al., 2001), squamous cell carcinomas, both in situ and invasive, also occurred with increasing frequency in p27 heterozygous and knockout mice compared to the wild type, suggesting a role for p27 loss in the pathogenesis of SCC as well. Our previous results suggest that the higher rate of SCC observed in mice treated with carcinogen alone (Xu et al., 2000) is not dependent on gastroesophageal reflux, in contrast to the BAA induced in this model. Nevertheless, flavopiridol also effectively prevented SCC in the context of this model.
Cancers that developed in mice treated with flavopiridol were significantly smaller than the cancers identified in diluent-treated animals. These data raise the possibility that in flavopiridol-treated mice, cancers grew with a compromised proliferative rate, perhaps as a result of flavopiridol-mediated cdk inhibition. Deregulated cdk activity occurs universally in human cancer (Sherr, 1996) . Genetic and epigenetic events result in overexpression of cyclins or absent or diminished levels of cdk inhibitors, which promotes Rb phosphorylation, drives cell cycle progression and provides tumor cells with a selective growth advantage. In BAA, overexpression of cyclin D1 occurs in approximately 50% of cases (Jenkins et al., 2002) , leading to increased activity of cdk4 and cdk6 and loss of growth control. The significantly lower levels of cyclin D1 expression in tumors from flavopiridol treated mice, in addition to the one tumor with phospho-Rb downregulation, suggest that cdk inhibition by flavopiridol has been achieved in tumor cells, with modulation of molecular targets critical to the pathogenesis of BAA.
For sites specifically phosphorylated by cdk4, it cannot be distinguished whether the decrease is related to a direct effect on Rb phosphorylation or because of depletion of cyclin D1. However, the T821 phospho-Rb site has been reported to be specifically phosphorylated by cdk2 (Zarkowska and Mittnacht, 1997). We had adequate tissue to perform T821 staining in one DMSO and one flavopiridol-treated mouse tumor. We found reduced staining in both BE and the tumor from the flavopiridol-treated mouse (Figure 4) . This is consistent with a direct effect of flavopiridol on cdk2 activity and downstream Rb phosphorylation, rather than simply a secondary sequela of cyclin D1 depletion.
Tumors in flavopiridol-treated mice may also have been smaller because they were delayed in onset, only developing once resistance to flavopiridol manifested. This perhaps explains the tumor from a flavopiridoltreated mouse in which phospho-Rb was still detected. Further experiments with in vivo monitoring will be needed to distinguish whether the effect of flavopiridol is primarily due to a decreased proliferative rate of malignant cells or delay in onset of tumor initiation or both.
Chemoprevention with COX-2 inhibitors has previously been shown to be effective in a rat model of BE (Buttar et al., 2002) and has led to a randomized, placebo-controlled trial of celecoxib in patients with BE and dysplasia (Heath et al., 2003) . In this study, we have used the first mouse model of BE and BAA that incorporates the p27 deficiency critical to malignant progression in humans. The induction of BE and cancer by gastroduodenal-esophageal reflux and MBN administration in p27 knockout mice was significantly inhibited in flavopiridol-treated animals. In addition, we have confirmed the targeting of cyclin D1 by flavopiridol in vivo. Unfortunately, flavopiridol will most likely not be an appropriate agent for chemoprevention trials. Currently, the drug is given intravenously and the optimal dosing schedule is still in evolution. Phase I and II trials have demonstrated dose-limiting toxicities of diarrhea, asthenia, and neutropenia and clotting events, all of which may preclude chronic administration Shapiro et al., 2001; Tan et al., 2002) . Nonetheless, the potency of flavopiridol in this model suggests that cdk inhibition may be an effective form of chemoprevention. Importantly, several novel cdk inhibitors have been formulated for oral administration, including CYC202 (Pierga et al., 2003) , BMS-387032 (McCormick et al., 2003) and Imidazo[1,2-a]pyridines (Anderson et al., 2003) and have entered clinical trials.
Finally, the ability of a cdk inhibitor such as flavopiridol to target cyclin D1 and phospho-Rb suggests promise for the treatment of esophageal carcinoma. To address this possibility, experiments are underway in which administration of flavopiridol is delayed until after surgery and 20 weeks of carcinogen exposure. Our model may therefore be useful to determine if flavopiridol or other members of this class have preclinical activity against established BAA.
Materials and methods

Animals
A total of 121 p27 knockout Swiss-Webster mice were housed, one mouse per cage, in an environment with a 12-h light/dark 
Surgical procedure
The esophagojejunostomy, designed to result in gastroduodenal-esophageal reflux of gastric, bile, and pancreatic juices, was performed as previously described (Xu et al., 2000) . Mice, 8 weeks old, were used and the operation was performed through a midline abdominal incision with division of the esophagus immediately proximal to the esophagogastric junction. An ellipse of anterior wall of jejunum was excised 4 mm distal to the ligament of Treitz. The distal esophagus was then anastomosed to the jejunum at the enterostomy site. The animals were given water 2 h after the operation and food the following day.
Carcinogen N-Methyl-N-benzylnitrosamine (MBN) (Ash-Stevens, Inc., Detroit, MI, USA), a carcinogen with a predilection for inducing esophageal cancer, was diluted in a saline solution and given by intraperitoneal injection at a dose of 2.5 mg/kg. Treatment began 1 week after the operation and injections were continued once a week for the duration of the experiment (Xu et al., 2000) .
Flavopiridol
Following surgery, mice were separated into the experimental (n ¼ 71) and control (n ¼ 50) test groups. Tissue preparation, histopathologic analysis and IHC At 20 weeks after the operation, the mice were killed with an overdose of Phenobarbital administered intraperitoneally. The entire esophagus of each mouse was removed, including the esophagojejunostomy site. Tissue was processed as previously described (Xu et al., 2000) . The greatest diameter of invasive tumors was measured on hematoxylin and eosinstained slides on the image analyzer. Tumors were classified as adenocarcinomas, mixed adenosquamous carcinomas or squamous cell carcinomas. IHC was performed as previously described (Xu et al., 2000; Ellis et al., 2001) . Antibodies and dilutions used included anti-cyclin D1 (Lab Vision Corporation, Fremont, CA, USA; 1 : 100); anti-total Rb (BD Pharmingen, San Diego, CA, USA; 1 : 500); anti-phospho-Rb (pS242/252) (Biosource International, Camarillo, CA, USA; 1 : 2000); anti-cdx2 (Biogenex, Inc., San Ramon, CA, USA) and anti-PCNA (Pharmingen, San Diego, CA, USA; 1 : 3000).
